With more than 100,000 survivors and activists, we are the world's largest, most progressive
grassroots network of people fighting to end breast cancer forever. As the face and voice of the global breast cancer movement...
We are local activists in more than 120 cities and communities, mobilizing more than 1.7 million friends and neighbors each year through events like the Susan G. Komen Race for the Cure® Series.
We are advocates at the local, state and federal level, fighting for the screening and treatment
programs that save lives and the research that brings us closer to the cures.
We are global citizens working with local health groups around the world and through komen.org to help millions of women in nearly 200 countries overcome the social, cultural and economic barriers to breast health and treatment.
Paula Schneider is president and CEO of Susan G. Komen®, responsible for the strategic direction and day-to-day operation of Komen’s research, community health, public policy advocacy and global programs. Schneider brings a personal perspective to Komen’s mission as a breast cancer survivor whose mother died of metastatic breast cancer.
Learn more about Paula now.
Connie O’Neill has been involved with Susan G. Komen since 1992. She served as treasurer of the organization for two years and chaired the National Awards Luncheon in 1994. In 2000, she was again appointed Komen Board treasurer and has continued to serve in that role. In June 2016, O’Neill assumed the role of Chair of the Komen Board of Directors.Learn more about Connie now.
As chief financial officer for Susan G. Komen®, Bob Green is responsible for all financial matters affecting the world's largest breast cancer organization, including the oversight of Komen's financial, accounting, training and information technology systems. Green will guide financial strategy for operations at Komen's headquarters as well as its global network of Affiliates.Learn
more about Bob now.
As senior vice president, development for Susan G. Komen®, Christina Alford is responsible for leading Komen's Development, Major Gifts, CRM, Direct Marketing and Donor Services teams.Learn more about Christina now.
As senior vice president, affiliate network for Susan G. Komen®, Lori Maris provides guidance and direction to the Komen global headquarters team and local Affiliate leadership in matters related to governance, financial compliance/reporting, organizational development and structure, event planning and operations, mission delivery, fundraising and day-to-day Affiliate operations.Learn more about Lori now.
As vice president, information technology for Susan G. Komen®, Eric Montgomery is responsible for the IT function of the world's largest breast cancer organization. In this role, Montgomery oversees enterprise IT solutions for Komen's global infrastructure and operational needs.Learn more about Eric now.
As vice president, human resources for Susan G. Komen®, Catherine Olivieri oversees the people-related programs and policies to connect and align business to people strategies throughout the organization. This includes talent acquisition, talent management, employee
benefits, compensation, employee relations, succession planning and organizational development. She assures that Susan G. Komen complies with requirements of ERISA, EEO and all federal, state and local statutes in support of the world's largest breast cancer organization.Learn more about Catherine now.
As General Counsel & Corporate Secretary, Adam Vanek oversees various responsibilities of the legal department, helps coordinate the development and implementation of legal processes and policies for Susan G. Komen and provides counsel to all departments within the organization.Learn more about Adam now.
As corporate controller for Susan G. Komen®, Ria Williams is responsible for the strategy and direction of the financial reporting and analysis functions for Headquarters and its global network of Affiliates. She assists the CFO with strategic and tactical matters as they relate to budget management, forecasting needs and strategic decision-making to help the organization achieve its mission of ending breast cancer forever.Learn more about Ria now.
As vice president, research and community health program operations for Susan G. Komen®, Victoria Wolodzko is responsible for Komen’s research, national community health and global grants, programs, and strategic partnerships, along with grant-making operations for the Affiliate Network. In this role, Wolodzko works closely with Komen’s mission advisors, including the Scientific Advisory Board, Komen Scholars, and Advocates in Science Steering Committee.Learn more about Victoria now.
Our Board of Directors governs and advises us in our endeavors to save lives and end breast cancer forever, and leads our efforts to fund the best science and equip the boldest communities in order to
make the biggest impact.
Jane Abraham was elected to Komen's Board of Directors on May 31, 2012, after serving as an interim board member and as a member of the Komen Advocacy Alliance Board of Directors. The wife of former Senator and U.S. Secretary of Energy Spencer Abraham, she has long been a breast cancer advocate, having actively participated for a number of years in both the annual Susan G. Komen Washington D.C. Race for the Cure (formerly known as the Global Race for the Cure) and Race for the Cure events in her home state of Michigan. She is Chair of the Board of the Susan B. Anthony List and just completed an 18-month assignment as Chair of the Congressional Commission on The American Museum of Women's History. Abraham is president of Abraham Strategies LLC., a strategic marketing firm and recently started a new business with her twin daughters, Abraham Retail Group Holding, LLC.
Kim Bohr is Executive Vice President of Operations for Fierce, Inc., a global, women-owned company that delivers results through improving workplace communication and culture. For more than 7 years, she’s been integral in creating and implementing sustainable growth strategies for the organization. Prior to Fierce, Bohr’s background includes broad operational experience in the telecom, human capital and business service industries. She received her International MBA from the University of Denver, having emphasized international policy and relations to drive cultural transformation. Bohr is a long-time supporter of Susan G. Komen to help drive awareness in honor of family and friends who have been impacted by cancer.
Peter D. Brundage recently retired as a Managing Director in the Investment Banking Division of Goldman Sachs, where he has worked for the past 32 years. During his career, Peter advised
companies throughout the Southwest on a wide range of transactions including financings, mergers & acquisitions and corporate governance. Peter has served on the Board of Directors of the AT&T Performing Arts Center, the Board of Governors of the Dallas Symphony Orchestra, the Board of Directors of the Dallas Symphony Foundation, the Executive Board of the SMU Cox School of Business and is past Chairman of the College Foundation of the University of Virginia. He currently serves on the Advisory Board of the Baylor Health Care System Foundation, the Finance Committee of the AT&T Performing Arts Center, is a national trustee for the Southwest Region of the Boys & Girls Clubs of America and serves on the Board of Directors of the Susan G. Komen Foundation. Peter earned an MBA from Dartmouth College in 1977 and a BA from the University of Virginia in 1975. Peter currently resides in Dallas, TX with his wife Susi.
Linda Custard, is a full-time volunteer with a wide range of experience in educational, cultural and social service boards. She has served as president of the Junior League of Dallas, vice chair of the United Way of Metropolitan Dallas, chair of the Board of Trustees of the Hockaday School, president of the Community Council of Greater Dallas and president of the Dallas Woman's Club. Presently, she serves as a trustee of Southern Methodist University and as a director of the Dallas Center for the Performing Arts Foundation. She has served on the Susan G. Komen board since 1982.
Alan D. Feld joined Akin Gump Strauss, Hauer and Feld, LLP in 1960 and is one of three senior executive partners in one of the world’s most respected law firms. He was appointed by the governor to the Texas State Securities Board in 1985 and served as the board’s chairman through 1991. In 1998 he was honored by the Southern Methodist University Dedman School of Law with the establishment of the Alan D. Feld Professorship. He currently serves as chairman of the Southern Methodist University Dedman School of Law’s executive board. He has served on the American Bar Association Commission on Opportunities for Minorities in its Profession. He was a member of the board of directors of the Dallas Citizen Council, a trustee of Southern Methodist University, board of visitors member for UT Southwestern University Hospitals and Clinics, board of visitors member at the University of Texas M.D. Anderson Cancer Center, and a former board member of the ARC, Timberlawn Psychiatric Research Foundation, Dallas Symphony Orchestra and Brandeis University.
Janet Dunn Frantz, a 15-year breast cancer survivor, joined the Komen Board in 2015 as one of two board members nominated by Komen’s Affiliate Network. Frantz previously served as Board President and Board Secretary of the Komen Virginia Blue Ridge Affiliate. She is an avid Komen supporter, participating in 3-Day walks and leading a top fundraising team in the Virginia Blue Ridge Komen Race for the Cure. Frantz has a background in commercial banking and spent her entire career with Bank of America and predecessor banks. Janet received a Bachelor of Arts in Economics from Wake Forest University.
Dan Glennon joined the Board in 2015. He is currently
the Chief Financial Officer of World 50. Previously, he was Chief Operating Officer and Chief Financial Officer at SPANX. Prior to joining SPANX, Glennon
held a number of strategic financial roles, including serving as Executive Vice President and Chief Financial Officer of Teavana through their IPO and eventual sale to Starbucks in 2012. Glennon earned his Bachelor of Business Administration degree from the University of Georgia and his MBA from Harvard.
Melissa Maxfield, Senior Vice President, Federal Government Affairs, for Comcast NBCUniversal, joined the Komen Board in 2015. In her role with Comcast NBCUniversal, she was honored as one of MultiChannel News’ Wonder Women for 2015 and named among the Most Powerful Women in Cable in 2012, 2013 and 2014 by CableFAX: The Magazine. Prior to joining Comcast in 2003, Maxfield served as the top staffer for Senate Majority Leader Tom Daschle (SD) and Senator Bob Kerrey (NE). She received her Bachelor’s Degree in Political Science from Randolph-Macon Woman’s College in Lynchburg, VA.
Dr. Olufunmilayo “Funmi” Olopade, M.D., F.A.C.P. currently serves as one of the Komen Scholars, an advisory group of 70 distinguished scholars and leaders in breast cancer research who participate in Komen's scientific peer review process. As a widely respected leader in breast cancer research, Dr. Olopade’s work has helped scientists around the globe gain a greater understanding of breast cancer. A highly skilled hematology oncologist with proven expertise in cancer risk assessment, Dr. Olopade is an expert on individualized treatment for breast cancer as well as quality of life concerns for breast cancer patients. She currently serves as Director of the Center for Clinical Cancer Genetics and Professor of Medicine and Human Genetics at the University of Chicago.
Andrew Robinson, joined the Komen Board in 2017, He is currently the Chief People Officer at Starr Restaurants and most recently he was the Chief People & Culture Officer at TGI Fridays global restaurant brand. He brings three decades of senior leadership experience in the restaurant and retail industry with as a strategic business leader with significant success driving corporate core mission and values, business strategy and organizational transformation across various industries. Andrew has an Bachelors of Business Administration and an MBA from Howard University.
Meghan Shannon, shareholder in the business law practice at Reinhart Boerner Van Deuren s.c. in Milwaukee, Wisconsin. She joined the Komen board in 2015. For the past six years, Shannon has been actively involved with the Komen Southeastern Wisconsin Affiliate, where she served as Board President and Treasurer. Shannon also was nominated through Komen’s Affiliate Network and brings experience in many areas of corporate, business and finance law. She received her undergraduate degree in Accounting from the University of Notre Dame and her law degree from the University of Wisconsin law school. She is a certified public accountant.
Trish Wheaton joined the Komen Board in 2016. Based in New York City, she has held executive leadership roles in two of WPP’s largest global agencies, Young & Rubicam Advertising and Wunderman. At Y&R she was Global Managing Partner and President/Founder of INSPIRE, a
multi-disciplinary practice focused on sustainability marketing. Previously Wheaton served as CMO of Wunderman, a global digital agency, and headed
Wunderman offices in Canada and the U.K. In 2013 she was inducted into the Marketing Hall of Femme, joining an elite group of women leading marketing
today. After graduating from Gustavus Adolphus College, Wheaton was a U.S. Peace Corps Volunteer to Kenya. She holds a master’s degree from the University of Minnesota.
Angela Zepeda joined the Komen Board in 2016. She is SVP, Business Development at INNOCEAN USA, a global advertising agency working with clients such as Hyundai, KIA, Genesis, Taylor Made, Champion, Finish Line and many others. Angela is responsible for leading and managing all marketing and growth initiatives for the agency’s U.S. footprint. Prior to INNOCEAN, Angela spent over a decade at Campbell-Ewald Los Angeles in addition to holding positions at some of LA’s most respected agencies, including TBWA/Chiat Day, Team One, Rapp Collins, Doner, and FCB. She has a wide background in several industrial sectors including automotive, healthcare, education, financial services, and packaged goods, in addition to expertise in marketing to women. Angela holds an MBA from the University of Southern California and a Bachelor of Arts degree in Communications/Advertising from California State University, Fullerton.
Nancy G. Brinker is regarded as the leader of the global breast cancer movement. Her journey began with a simple promise to her dying sister, Susan G. Komen, that she would do everything possible to end the shame, pain, fear and hopelessness caused by this disease. In one generation, the organization that bears Susan's name has changed the world. Learn more about Nancy now.
The Scientific Advisory Board (SAB) provides strategic guidance and direction for our research and scientific programs. It plays a key role in guiding and prioritizing Komen’s global research investment and serves as the executive committee of the Komen Scholars. The SAB is led by the chief scientific advisors and is comprised of leaders in breast cancer research, clinical practice and advocacy who have made significant contributions to advancing the field and are committed to furthering Komen’s mission.
George Sledge, Jr., M.D., is Professor of Medicine and Pathology, and Chief of the Division of Oncology in the Department of Medicine at Stanford University.
An internationally-recognized clinical trialist and pioneer in the development of novel therapies for breast cancer, Dr. Sledge directed the first large, nationwide trial that studied the efficacy of paclitaxel as a therapy for advanced breast cancer. He has led many nationwide clinical trials involving new therapies for breast cancer. His research focuses on molecular and tumor biology, growth factors and anti-angiogenic therapy. His Komen-funded research focuses on finding new, druggable targets in triple negative breast cancers, investigating the process of angiogenesis (tumors forming new blood vessels) and identifying genetic clues that will decipher how angiogenesis occurs. He is also evaluating new technologies that capture tumor cells circulating in the blood stream, which may provide doctors with better tools to understand and treat metastatic breast cancer. Dr. Sledge is also one of the experts involved with Komen’s big data initiative. He was awarded the Brinker Award for Scientific Distinction in 2006 for his outstanding research.
more about Dr. Sledge in Voices of Impact.
Jennifer Pietenpol, Ph.D., is the Executive Vice President for Research at Vanderbilt University Medical Center, Director of the Vanderbilt-Ingram Cancer Center, the B.F. Byrd Jr. Professor of Molecular Oncology, and Professor of Biochemistry, Cancer Biology and Otolaryngology at Vanderbilt University School of Medicine.
Dr. Pietenpol’s early research focused on the signaling of p53 family in breast cancer; p53 is a tumor suppressor gene (controls cell death) and is one of the most commonly mutated genes in cancer. More recently, Dr. Pietenpol has combined her research expertise in molecular genetics with bioinformatics and statistics to advance our knowledge of the key driving signaling molecules in triple negative breast cancer (TNBC). Dr. Pietenpol’s Komen funding supports research that identified molecular subtypes of TNBC and is now determining the molecular underpinnings of these distinct subtypes. The results from her laboratory-based work are being translated to several clinical trials investigating targeted therapies for TNBC patients, with the goal of helping oncologists determine the most appropriate and precise treatment for breast cancer patients.
Myles A. Brown, M.D., is Professor of Medicine at Harvard Medical School. Trained as a medical oncologist, he is currently Director of the Center for Functional Cancer Epigenetics at Dana-Farber Cancer Institute.
Dr. Brown’s research focuses on understanding the role of steroid hormones and their receptors in breast and prostate cancers. A translational researcher, he studies how female hormones such as estrogen and progesterone and male hormones such as testosterone regulate the growth of hormone-dependent cancers. His laboratory spans the full spectrum of research into hormone action from very basic work identifying the proteins and genes regulated by steroid hormones and their receptors to studies of actual patient tumors to identify mechanisms of therapeutic resistance. Through his Komen-funded research, Dr. Brown is currently investigating how estrogen receptor-positive breast cancers become resistant to endocrine therapy with the goal of using this knowledge to develop new breast cancer treatments.
Karen A. Gelmon, M.D., F.R.C.P.C., is Professor of Medicine and Head of the Division of Medical Oncology at the University of British Columbia and a Medical Oncologist at the British Columbia Cancer Agency. She is also Senior Scientist and Clinical Leader of the Experimental Therapeutics Department at the British Columbia Cancer Research Centre.
Her research bridges her clinical practice with her passion for research. She focuses on developing early drug trials of novel agents and improved treatment options for individuals with breast cancer. Her work spans Phase I, II, and III clinical trials as well as research to understand the character of cancer and its effect on patients. Dr. Gelmon’s Komen-funded grant helps to support two clinical trials: 1) determining which patients respond best to the treatment paclitaxel and why, and 2) investigating the DNA of patients with BRCA-related cancers to learn why some responded to a treatment called olaprib and others did not. Dr. Gelmon is also working on a trial of “spatial heterogeneity:” how genomic changes in different regions of the breast cancer correlate with circulating DNA.
Cheryl L. Jernigan, CPA, F.A.C.H.E., is a 20-year breast cancer "thriver" and cancer research advocate. She was previously CEO of the Kansas City Area Hospital Association, and has over 20 years of experience in health policy, advocacy and community/national leadership on behalf of hospitals.
She is Chair of the Breast Cancer Prevention Center’s Advocate Advisory Board for The University of Kansas Medical Center and The University of Kansas Hospital, and she is the Lead Advocate of Patient & Investigator Voices Organizing Together (PIVOT), a new University of Kansas Cancer Center initiative. Ms. Jernigan is a founding and current board member and Chair of the Strategic Mission Committee of the Greater Kansas City Komen Affiliate, and a member of the Steering Committee of Komen’s Advocates In Science program. An active research advocate, Ms. Jernigan is a member of many clinical trial initiatives, including the National Cancer Institute’s Central Institutional Review Board for Adult Late Phase Clinical Trials. Ms. Jernigan is also one of the experts involved with Komen’s big data initiative.
Lisa A. Newman, M.D., M.P.H., FACS, FASCO is a surgical oncologist, and Director of the Breast Oncology Program for the multi-hospital Henry Ford Health System (HFHS) in metropolitan Detroit, MI. She is the Founding Medical Director for the HFHS International Center for the Study of Breast Cancer Subtypes. Dr. Newman holds an appointment on the NIH Advisory Council for the Institute of Minority Health and Disparities.
Her primary research has focused on ethnicity-related variation in breast cancer risk and outcome. She oversees an international breast cancer research and training program involving the University of Michigan, the Henry Ford Health System, the Komfo Anoyke Teaching Hospital in Kumasi, Ghana, the Korle Bu Teaching Hospital in Accra, Ghana, and the St. Paul’s Millenium Hospital in Addis Ababa, Ethiopia. This program has focused on studying triple negative breast cancer in women with African ancestry. Her Komen Scholar grant will study triple negative breast cancer (TNBC) subtypes in diverse populations, and create a new research field of anthropologic oncology, which can define root causes of breast tumor progression based upon the study of population migration patterns and reproductive history.
Eric P. Winer, M.D., is Professor of Medicine at Harvard Medical School and Chief, Division of Women's Cancers and the Thompson Chair in Breast Cancer Research at Dana-Farber Cancer Institute. He is the 2009 recipient of the A. Clifford Barger Excellence in Mentoring Award from Harvard Medical School.
Dr. Winer has devoted his professional career to the treatment of individuals with breast cancer and breast cancer research. He has designed and led phase I, II, and III clinical trials. He has collaborated closely throughout his career with psychosocial researchers, health services researchers, and both basic and translational scientists. His group at Dana-Farber conducts a broad array of breast cancer research with the goal of extending the lives of individuals with breast cancer and minimizing suffering and morbidity from the disease. Dr. Winer’s research interests also include quality of life, psychosocial aspects of cancer, medical decision making, and doctor-patient communication. His Komen-funded research is focused on reducing racial disparities in breast cancer and is also looking at preoperative therapies for patients with HER+ breast cancer.
Melissa Bondy, Ph.D.
Baylor College of Medicine
SAB member 2007-2010
Komen Scholar 2010-2017
Powel Brown, M.D., Ph.D.
The University of Texas M.D. Anderson Cancer Center
SAB member 2007-2017
H. Kim Lyerly, M.D.
Duke Comprehensive Cancer Center
Scientific Advisory Board 2007-2010
Komen Scholar 2010-2013
Amelie Ramirez, Dr.P.H.
The University of Texas Health Science Center at San Antonio
San Antonio, TX
Saraswati Sukumar, Ph.D.
Johns Hopkins University School of Medicine
SAB member 2007-2010
Our mission advisors are rock stars—the best and brightest researchers, clinicians, advocates and other experts who help guide and implement our mission programs. Thanks to their efforts, we’re driving discovery, affecting change and accelerating progress in the fight against breast cancer.
The Scientific Advisory Board (SAB) provides strategic guidance and direction for our research and scientific programs. It helps prioritize our global research investment and serves as the executive committee of the Komen Scholars. Learn more about the esteemed members now.
The Komen Scholars are an advisory group of 60 distinguished leaders in breast cancer research and advocacy. Representing more than 32 institutions in seven countries, their expertise spans everything from clinical research, laboratory research, pathology, prevention, radiation oncology, surgery and other disciplines and specialties. They contribute to our programs, activities and events in many ways, most notably our scientific peer review process, and act as our ambassadors in communities around the U.S. and the world. Get to know our Komen Scholars now.
The Advocates in Science Steering Committee is comprised of seven advocates who’ve demonstrated their dedication and leadership in breast cancer advocacy. The committee works closely with Komen staff, both locally and nationally, to develop the strategy for the AIS program, expand its community of members and leverage the benefits of effective breast cancer research advocacy. They are also active members of either the Komen Scholars or the Scientific Advisory Board. Get to know the members of our AIS steering committee now.
Thanks to survivors, volunteers and activists dedicated to the fight against breast cancer, the Komen Affiliate Network is the nation's largest private funder of community-based breast health education and breast cancer screening/treatment site.
To make a request for a representative from Susan G. Komen to attend or speak at a third-party event, please fill out this form. Please complete every field on the form with as much detail as possible.
Komen leadership attendance at events is subject to availability, and we are unable to guarantee fulfillment of every request. After submitting the form, you will be notified when your request has been processed and whether a Komen representative will be able to attend.
Careers & Opportunities